GUILIN SANJIN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.56 CNY | +0.40% |
|
-2.86% | -13.32% |
| 04-26 | Guilin Sanjin Pharmaceutical Co., Ltd. Proposes Final Dividend for 2023 | CI |
| 04-25 | Guilin Sanjin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 1.96B 270M 21.35B | Sales 2023 | 2.17B 299M 23.65B | Capitalization | 8.51B 1.17B 92.74B |
|---|---|---|---|---|---|
| Net income 2022 | 330M 45.45M 3.59B | Net income 2023 | 421M 57.99M 4.59B | EV / Sales 2022 | 3.37 x |
| Net cash position 2022 | 961M 132M 10.47B | Net cash position 2023 | 878M 121M 9.56B | EV / Sales 2023 | 3.52 x |
| P/E ratio 2022 |
23.6
x | P/E ratio 2023 |
20.1
x | Employees | 2,615 |
| Yield 2022 |
6.05% | Yield 2023 |
4.14% | Free-Float | 21.18% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.40% | ||
| 1 week | -2.86% | ||
| Current month | -6.41% | ||
| 1 month | -13.44% | ||
| 3 months | -13.38% | ||
| 6 months | -14.44% | ||
| Current year | -13.32% |
1 week
12.42
13.04
1 month
12.4214.47
Current year
11.2815.73
1 year
11.2818.45
3 years
10.5921.67
5 years
10.5921.67
10 years
10.5937.49
| Managers | Title | Age | Since |
|---|---|---|---|
Xun Zou
CHM | Chairman | 48 | 21/12/10 |
Yuan Gang Xie
DFI | Director of Finance/CFO | 63 | 20/12/07 |
Zhun Zou
BRD | Director/Board Member | 44 | 25/07/13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yuan Gang Xie
DFI | Director of Finance/CFO | 63 | 20/12/07 |
Ling Xia Mo
BRD | Director/Board Member | 60 | 12/04/19 |
Xun Zou
CHM | Chairman | 48 | 21/12/10 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 32 M€ | +3.96% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/24 | 12.56 | +0.40% | 1 779 648 |
| 20/06/24 | 12.51 | -1.81% | 2,032,700 |
| 19/06/24 | 12.74 | -1.39% | 1,692,861 |
| 18/06/24 | 12.92 | -0.15% | 1,371,408 |
| 17/06/24 | 12.94 | +0.23% | 1,345,639 |
End-of-day quote Shenzhen S.E., June 20, 2024
More quotes
Guilin Sanjin Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research, production and distribution of Chinese patent medicines, as well as distribution of products. The Company's main products portfolio consists of watermelon frost series, including watermelon frost lozenge, guilin watermelon frost and watermelon frost throat lozenge, mainly used for treatment of throat and mouth diseases; sanjin tablets, mainly used for treatment of urinary system infection, as well as naomaitai capsules, mainly used for treatment of cardiovascular and cerebrovascular diseases. It distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.32% | 1.01B | |
| +34.14% | 5.82B | |
| -30.04% | 3.65B | |
| +1.55% | 3.13B | |
| -22.68% | 2.68B | |
| -8.17% | 2.31B | |
| +42.02% | 1.86B | |
| +45.22% | 1.45B | |
| -12.58% | 1.44B | |
| -27.42% | 1.36B |
- Stock Market
- Equities
- 002275 Stock
